Abstract
A series of N,N-Bis(2-hydroxylbenzyl)-1,2-ethanediamine derivatives and its schiff bases were synthesized, characterized and screened for in vitro antimicrobial activity against Staphylococcus aureus, Pseudomonas aeruginosa and Salmonella enterica. Result indicated that the ethylenediamine derivatives, N,N-Bis(2-hydroxy-5-bromobenzyl)-1,2- ethanediamine (21), and N,N-Bis(2-hydroxy-5-chlorobenzyl)-1,2-ethanediamine (22) showed the most favorable antimicrobial activity exhibiting LC50 of 11.6 and 8.79 μM against S.enterica, 86 and 138 μM against P. aeruginosa, and 140 and 287 μM against S. aureus, respectively. These compounds displayed highest level of resistance with S. aureus. Thus, the high level of activity seen with the compounds (21, 22) suggests that these compounds could serve as the leads for development of novel synthetic compounds with enhanced antimicrobial activity.
Keywords: Schiff base, N, N-ethylenediamine, Antimicrobial activity
Letters in Drug Design & Discovery
Title: Synthesis and Antimicrobial Activity of N,N-Bis(2-hydroxylbenzyl)-1,2- ethanediamine Derivatives
Volume: 7 Issue: 3
Author(s): Musiliyu A. Musa, M. Omar F. Khan, Arden Aspedon and John S. Cooperwood
Affiliation:
Keywords: Schiff base, N, N-ethylenediamine, Antimicrobial activity
Abstract: A series of N,N-Bis(2-hydroxylbenzyl)-1,2-ethanediamine derivatives and its schiff bases were synthesized, characterized and screened for in vitro antimicrobial activity against Staphylococcus aureus, Pseudomonas aeruginosa and Salmonella enterica. Result indicated that the ethylenediamine derivatives, N,N-Bis(2-hydroxy-5-bromobenzyl)-1,2- ethanediamine (21), and N,N-Bis(2-hydroxy-5-chlorobenzyl)-1,2-ethanediamine (22) showed the most favorable antimicrobial activity exhibiting LC50 of 11.6 and 8.79 μM against S.enterica, 86 and 138 μM against P. aeruginosa, and 140 and 287 μM against S. aureus, respectively. These compounds displayed highest level of resistance with S. aureus. Thus, the high level of activity seen with the compounds (21, 22) suggests that these compounds could serve as the leads for development of novel synthetic compounds with enhanced antimicrobial activity.
Export Options
About this article
Cite this article as:
Musa A. Musiliyu, F. Khan Omar M., Aspedon Arden and Cooperwood S. John, Synthesis and Antimicrobial Activity of N,N-Bis(2-hydroxylbenzyl)-1,2- ethanediamine Derivatives, Letters in Drug Design & Discovery 2010; 7 (3) . https://dx.doi.org/10.2174/157018010790596678
DOI https://dx.doi.org/10.2174/157018010790596678 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacophore Modeling Methods in Focused Library Selection – Applications in the Context of a New Classification Scheme
Combinatorial Chemistry & High Throughput Screening Dendritic Cells in Innate Immune Responses Against HIV
Current Molecular Medicine Chemical and Bioactive Diversities of the Genus Chaetomium Secondary Metabolites
Mini-Reviews in Medicinal Chemistry The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design The Relative Transcription Index: A Gene Expression Based Metric for Prioritization of Drug Candidates
Combinatorial Chemistry & High Throughput Screening Occurrence of DAT1 (VNTR) Polymorphism in Individuals with HIV Infection
Current Pharmacogenomics and Personalized Medicine Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis
Current Pharmaceutical Biotechnology Adjunctive Immunotherapeutic Efficacy of N-Formylated Internal Peptide of Mycobacterial Glutamine Synthetase in Mouse Model of Tuberculosis
Protein & Peptide Letters NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects
Current Topics in Medicinal Chemistry SAR and Anti-Mycobacterial Activity of Quinolones and Triazoloquinolones: An Update
Anti-Infective Agents Peptide Nucleic Acids (PNAs) as Diagnostic Devices for Genetic and Cytogenetic Analysis
Current Pharmaceutical Design Use of Peptide Libraries for Identification and Optimization of Novel Antimicrobial Peptides
Current Topics in Medicinal Chemistry Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry The Cell-Wall Core of Mycobacterium tuberculosis in the Context of Drug Discovery.
Current Topics in Medicinal Chemistry Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Current Drug Targets Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Current Drug Metabolism Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design The Role of Exosomes in Infectious Diseases
Inflammation & Allergy - Drug Targets (Discontinued)